Publications by authors named "N Hatta"
Article Synopsis
- Treatment options for extramammary Paget's disease (EMPD) vary based on disease stage, with distinct survival rates observed among different stages.
- A study of 643 EMPD cases in Japan revealed that curative surgery was the most common treatment for early stages, while chemotherapy was primarily used for more advanced stages.
- Female sex was linked to a higher risk of local relapse in early stages, while initial curative surgery significantly improved survival rates in mid to advanced stages, indicating a need for further research.*
Article Synopsis
- Anti-PD-1 immunotherapy is less effective for Asian patients with advanced BRAF V600-mutant melanoma, leading researchers to consider alternative first-line treatments.
- A study analyzed treatment outcomes for 336 Asian patients using BRAF/MEK inhibitors, anti-PD-1, and PD-1/CTLA-4 combinations, revealing BRAF/MEKi had the best objective response rates and progression-free survival.
- The results suggested that BRAF/MEKi may be preferred over anti-PD-1 treatments for these patients, particularly in second-line settings, highlighting the need for tailored treatment approaches based on patient demographics.
Malignant vulvar melanoma (VuM) and vaginal melanoma (VaM) represent a unique subgroup of rare malignant melanomas with critical biological properties that differ from other cancers. In Japan, adequate surveys have yet to be conducted. This study aimed to elucidate the clinicopathological demographics and outcomes of VuM and VaM in Japan.
View Article and Find Full Text PDFBasal cell carcinoma is the most common type of skin cancer, and surgical excision with clear margins is the standard of care. Surgical margins are determined based on risk factors (high or low risk) for recurrence according to the National Comprehensive Cancer Network and Japanese basal cell carcinoma guidelines. The clarity of the clinical tumor border (well-defined or poorly defined) is considered a risk factor, and significant discrepancies in the judgment of clinical tumor borders among dermato-oncologists may occur.
View Article and Find Full Text PDF